B-Cell Lymphomas Coverage from Every Angle

Leo I. Gordon, MD, on Using CAR T-Cell Therapy Earlier for DLBCL: Time to Change the Standard of Care?

Posted: Thursday, February 10, 2022

Leo I. Gordon, MD, of Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, talks about three major studies—ZUMA-7, TRANSFORM, and BELINDA—suggesting it may be time to begin using CAR T-cell therapy for second-line treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The therapy is already approved as a third- or fourth-line treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.